Like Ozempic, it requires prior authorization and documentation of previous medication trials
CJC-1295 Teichman SL et al
Gastrointestinal Very common (10% or more): Gastrointestinal adverse reactions (up to 73%), nausea (up to 44%), vomiting (up to 36%), diarrhea (up to 30%), constipation (up to 24.2%), abdominal pain (up to 20%) Common (1% to 10%): Dyspepsia, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, viral gastroenteritis, increased amylase, increased lipase, dry mouth, severe gastrointestinal adverse reactions, delayed gastric emptying Uncommon (0.1% to 1%): Acute pancreatitis, appendicitis Frequency not reported : Hemorrhoids, hiccups Postmarketing reports : Ileus, intestinal obstruction, severe constipation, hiccups, acute pancreatitis, necrotizing pancreatitis In clinical trials in adults using the subcutaneous injection for weight reduction, 73% of treated patients reported gastrointestinal adverse reactions, including severe reactions (4.1%)

Epigenetic basis of sensitization to stress, affective episodes, and stimulants: implications for illness progression and prevention
Nausea rates climbed to 18-36% depending on the titration speed, and gastrointestinal complaints became more common across the board
How a Retatrutide 4mg Dose Fits Into a Broader Research Range Research involving Retatrutide has typically tested several levels as part of a phased design, moving from lower starting amounts toward higher figures only after earlier stages were reviewed